Anti-MAL (full length) polyclonal antibody

The energy balance approach is one of the design approaches approved in fall protection standards Z359.6, Z259.16 and SS 607 to ensure that horizontal lifeline systems (HLLSs) are adequately designed. However, this study found that theoretical calculations predicting the total fall distance (h(TFD)) and maximum arrest load (MAL) using an energy balance approach need to be corrected before they can be used safely. Based on the data from 48 drop tests, the authors determined that energy balance calculations differ significantly from the empiricalh(TFD)and MAL values of HLLSs. As a result, further correction factors are introduced into the theoretical calculations to estimateh(TFD)and MAL conservatively. These correction factors are estimated from a regression equation derived based on experimental results and theoretical calculations.

Background Neuronal ceroid lipofuscinosis type 5 (CLN5) is a rare form of neuronal ceroid lipofuscinoses (NCLs) which are a group of inherited neurodegenerative diseases characterized by progressive intellectual and motor deterioration, visual failure, seizures, behavioral changes and premature death. CLN5 was initially named Finnish variant late infantile NCL, it is now known to be present in other ethnic populations and with variable age of onset. Few CLN5 patients had been reported in Chinese population. Case presentation In this paper, we report the symptoms of a Chinese patient who suffer from developmental regression and grand mal epilepsy for several years. The DNA was extracted from peripheral blood of proband and both parents, and then whole exome sequencing was performed using genomic DNA. Both sequence variants and copy number variants (CNVs) were analyzed and classified according to guidelines. As the result, a novel frameshift mutation c.718_719delAT/p.Met240fs in CLN5 and a de novo large deletion at 13q21.33-q31.1 which unmasked the frameshift mutation were identified in the proband. Despite the large de novo deletion, which can be classified as a pathogenic copy number variant (CNV), the patient's clinical presentation is mostly consistent with that of CLN5, except for early developmental delay which is believed due to the large deletion. Both variants were detected simultaneously by exome sequencing. Conclusions This is the first report of whole gene deletion in combination with a novel pathogenic sequence variant in a CLN5 patient. The two mutations detected with whole exome sequencing simultaneously proved the advantage of the sequencing technology for genetic diagnostics.